Nicole Balmaceda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nicole Balmaceda has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Aaron James Scott
University of Arizona Cancer Center, Tucson, Arizona
23 shared publications - Adrian T A Dominguez
Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado
23 shared publications - Adrie Van Bokhoven
Department of Pathology, University of Colorado Denver, Anschutz Medical Campus; Aurora, CO, 80045, USA
23 shared publications - Alexis D. Leal
Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado
23 shared publications - Cameron A. Binns
Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado
23 shared publications - Christopher Hanyoung Lieu
University of Colorado Cancer Center, Aurora, CO
23 shared publications
Latest Publications
- Open Access
- 20 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Supplementary Figure S2. Human and murine immune system in peripheral lymphatic organs and tumor of HIS-BRGS mice bearing CRC307P PDX.
- 20 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Supplementary Figure S2. Human and murine immune system in peripheral lymphatic organs and tumor of HIS-BRGS mice bearing CRC307P PDX.
- Open Access
- 20 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Supplementary Figure S5. CONSORT
- 20 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Supplementary Figure S5. CONSORT
- Open Access
- 20 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Role of mouse myeloid cells in CRC307P-bearing HIS-BRGS mice treated with combinations of ALX90, cetuximab, pembrolizumab, and LC. A, Flow cytometric gating strategy for quantification of mouse (mCD45+) myeloid populations: PMNs (Ly6G+), M1 (CD38+) and M2 (CD206+) macrophages (MO: F4/80+), and expression of mouse MHC class I and class II. B, Quantification of human (left, CD11b+ CD14+, CD33+, or CD11c+) and mouse (right, mCD45+) myeloid populations in tumors of HIS-CRC307P-BRGS mice among treatment groups: vehicle (V), ALX90 (A), cetuximab (C) + pembrolizumab (CP), ACP (ALX90 + cetuximab + pembrolizumab), LC, and ACP + LC. C, Ratios of PMN/MO and M1/M2 of F4/80 macrophages among mouse myeloid cells. D, Correlation of mouse myeloid populations with tumor growth (SGR) among triple therapy (ACP, top) and triple therapy following LC treatments (ACP + LC, bottom). Statistics of linear correlation are provided; *, P < 0.05; **, P < 0.001; ***, P < 0.0001.
- 20 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Role of mouse myeloid cells in CRC307P-bearing HIS-BRGS mice treated with combinations of ALX90, cetuximab, pembrolizumab, and LC. A, Flow cytometric gating strategy for quantification of mouse (mCD45+) myeloid populations: PMNs (Ly6G+), M1 (CD38+) and M2 (CD206+) macrophages (MO: F4/80+), and expression of mouse MHC class I and class II. B, Quantification of human (left, CD11b+ CD14+, CD33+, or CD11c+) and mouse (right, mCD45+) myeloid populations in tumors of HIS-CRC307P-BRGS mice among treatment groups: vehicle (V), ALX90 (A), cetuximab (C) + pembrolizumab (CP), ACP (ALX90 + cetuximab + pembrolizumab), LC, and ACP + LC. C, Ratios of PMN/MO and M1/M2 of F4/80 macrophages among mouse myeloid cells. D, Correlation of mouse myeloid populations with tumor growth (SGR) among triple therapy (ACP, top) and triple therapy following LC treatments (ACP + LC, bottom). Statistics of linear correlation are provided; *, P < 0.05; **, P < 0.001; ***, P < 0.0001.
- Open Access
- 20 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Supplementary Figure S6. Survival outcomes of the trial.
- 20 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Supplementary Figure S6. Survival outcomes of the trial.
- Open Access
- 20 November 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Table 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
- 20 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Table 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
- Open Access
- 20 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Supplementary Figure S4. T cell subsets in peripheral lymphatic organs and tumor properties of HIS-BRGS mice bearing CRC307P PDX.
- 20 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Supplementary Figure S4. T cell subsets in peripheral lymphatic organs and tumor properties of HIS-BRGS mice bearing CRC307P PDX.
- Open Access
- 20 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Supplementary Figure S3. Triple therapy (ALX90, cetuximab, and pembrolizumab) activates human T cells and slows tumor growth of CRC307P CRC MSS PDX in HIS-BRGS mice with liposomal clodronate treatment (LC).
- 20 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Supplementary Figure S3. Triple therapy (ALX90, cetuximab, and pembrolizumab) activates human T cells and slows tumor growth of CRC307P CRC MSS PDX in HIS-BRGS mice with liposomal clodronate treatment (LC).
- Open Access
- 20 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Supplementary Figure S7. Distance between tumor cells and CD4+ and CD8+ T cells in archival tumor tissue by immunohistochemistry.
- 20 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Supplementary Figure S7. Distance between tumor cells and CD4+ and CD8+ T cells in archival tumor tissue by immunohistochemistry.
- Open Access
- 20 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Supplementary Table 4. Treatment-related adverse events by CTCAE v5.0, grade 1-4 occurring in at least 10% of patients and all grade 5, at the patient level.
- 20 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Supplementary Table 4. Treatment-related adverse events by CTCAE v5.0, grade 1-4 occurring in at least 10% of patients and all grade 5, at the patient level.